ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Note Regarding Forward-Looking Information and Factors That May Affect Future Results
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes and other financial information included in this Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading "Forward-Looking Statements" elsewhere in this Report on Form 10-Q. Forward-looking statements include those preceded by, followed by or including the words "will," "expect," "intended," "anticipated," "believe," "project," "forecast," "propose," "plan," "estimate," "enable," and similar expressions, including, for example, statements about our business strategy, our industry, our future profitability, growth in the industry sectors we serve, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions, and estimates and projections of future activity and trends in our industry. These forward-looking statements are not guarantees of future performance. These statements are based on management's expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, most of which are difficult to predict and many of which are beyond our control, which include, but are not limited to: the risk that we continue to sustain prolonged losses and never achieve profitability, our ability to continue as a going concern, and risks related to protection and maintenance of our intellectual property. You should review the disclosure under the heading "Risk Factors" in this Current Report on Form 10-Q, in our prior annual report on Form 10-K, and the risk factors stated in our Current Report on Form 8-K filed May 1, 2018, for a discussion of important factors and risks that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
On April 25, 2018, our wholly-owned subsidiary, WETM Acquisition Corp., a corporation formed in the State of Colorado on April 18, 2018, (the "Acquisition Sub"), merged with and into C-Bond Systems, LLC, a privately held Texas limited liability company ("C-Bond Systems, LLC"). Pursuant to this transaction (the "Merger"), C-Bond Systems, LLC was the surviving corporation and became our wholly-owned subsidiary. All of the outstanding membership interests of C-Bond Systems, LLC were converted into shares of our common stock, as described in more detail below.
As a result of the Merger, we acquired the outstanding equity of C-Bond Systems, LLC and will continue the existing business operations of C-Bond Systems, LLC. In accordance with "reverse merger" or "recapitalization" accounting treatment, our historical financial statements as of period ends, and for periods ended, prior to the Merger will be replaced with the historical financial statements of C-Bond Systems, LLC prior to the Merger, in all future filings with the SEC. In accordance with the "reverse merger" or "recapitalization" accounting treatment, the unaudited condensed consolidated interim financial statements for the period ended June 30, 2018 include the accounts of the Company and its wholly owned subsidiary, C-Bond Systems, LLC. The comparative historical financial statements for periods ended prior to the date of the Merger are the historical financial statements of C-Bond Systems, LLC.
Effective June 7, 2018, a majority of our shareholders and our board approved the change of our name to C-Bond Systems, Inc. and approved an increase in our authorized number of common shares from 100,000,000 to 500,000,000 shares of common stock and 1,000,000 shares of preferred stock. These changes became effective on July 18, 2018.
Recent Developments
Reverse Merger
On April 25, 2018, pursuant to the Merger Agreement, Acquisition Sub merged with and into C-Bond Systems, LLC, with C-Bond Systems, LLC remaining as the surviving entity and a wholly-owned operating subsidiary of our Company. The Merger was effective as of April 26, 2018, upon the filing of a Certificate of Merger with the Secretary of State of the State of Texas.
At the time a certificate of merger reflecting the Merger was filed with the Secretary of State of Texas, or the Effective Time, all of the outstanding Common Units of C-Bond Systems, LLC that were issued and outstanding immediately prior to the closing of the Merger were converted into an aggregate of 63,505,783 shares of our common stock. As a result, each common unit of C-Bond Systems, LLC was converted into approximately 3.23 shares of our common stock.
In addition, pursuant to the Merger Agreement, each option to purchase Common Units issued and outstanding immediately prior to the closing of the Merger was assumed and converted into an option to purchase an equivalent number of shares of our common stock and the exercise price of each such option was divided by the Conversion Ratio of 3.23. As a result, a total of 14,494,213 options were issued.
C-Bond Systems, LLC is considered the accounting acquirer in the Merger and we will account for the transaction as a recapitalization transaction because C-Bond System, LLC's former members received substantially all of the voting rights in the combined entity and C-Bond Systems, LLC's senior management represents all of the senior management of the combined entity.
The following discussion highlights C-Bond System Inc.'s results of operations and the principal factors that have affected our consolidated financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the consolidated statements of financial condition and consolidated results of operations presented herein. The following discussion and analysis are based on the Company's unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such condensed consolidated financial statements and the related notes thereto.
Private Placement
Concurrently with the closing of the Merger, we sold 3,100,000 shares of our common stock pursuant to a private placement for a purchase price of $0.40 per share, or the Offering Price.
Operating Overview
We are a nanotechnology company and the sole owner, developer and manufacturer of the patented C-Bond technology. We are engaged in the implementation of proprietary nanotechnology applications and processes to enhance properties of strength, functionality and sustainability of brittle material systems. We presently have a primary focus in the multi-billion dollar glass and window film industry with target markets in the United States and internationally. The C-Bond technology enables ordinary glass to dissipate energy by permeating the glass surface and detecting microscopic flaws and defects that are randomly distributed all over the glass surface. Our technology's unique qualities then work to locate and repair the identified surface imperfections that weaken the glass composite structure and ultimately act as failure initiators. The C-Bond formula is engineered to maintain original glass design integrity while increasing the mechanical performance properties of the glass unit.
Revenue is generated by the sale of products through distributors and directly to authorized dealers. C-Bond NanoShield sales are generated through large distribution channels. Sales of C-Bond I are made to authorized window film dealers who offer the product as an upsell during installation. The C-Bond II ballistic resistant system is sold on a project basis. The C-Bond II system is specified into project plans providing authorized dealers a competitive advantage.
Product sales are recognized when the product is shipped to the customer and title is transferred and are recorded net of any discounts or allowances.
We anticipate continued loses requiring either revenue generation to achieve sustained profitability or obtaining additional financial resources to maintain operations as well as research and development into product performance and new product verticals.
Critical Accounting Policies
The following discussion and analysis of our financial condition and results of operations are based upon our audited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Management continually evaluates such estimates, including those related to estimates for allowance for doubtful accounts on accounts receivable, the estimates for obsolete inventory, the useful life of property and equipment, assumptions used in assessing impairment of long-term assets, the fair value of a beneficial conversion feature, and the fair value of non-cash equity transactions. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Management believes the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the unaudited condensed consolidated financial statements.
Accounts receivable
The Company recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical bad debt experience, current receivables aging, and expected future write-offs, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general and administrative expense.
Inventory
Inventory, consisting of raw materials and finished goods, are stated at the lower of cost and net realizable value utilizing the first-in, first-out (FIFO) method. A reserve is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected net realizable value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the net realizable value. These reserves are recorded based on estimates and included in cost of sales.
Revenue recognition
In May 2014, FASB issued an update Accounting Standards Update ("ASU") ("ASU 2014-09") establishing Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017, requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. The Company adopted this standard in 2018 using the modified retrospective approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Based on an evaluation of the impact ASU 2014-09 will have on the Company's sources of revenue, the Company has concluded that ASU 2014-09 did not have a material impact on the process for, timing of, and presentation and disclosure of revenue recognition from customers.
The Company sells its products primarily to distributors and authorized dealers. Product sales are recognized when the product is shipped to the customer and title is transferred and are recorded net of any discounts or allowances.
Stock-based compensation
Stock-based compensation is accounted for based on the requirements of ASC 718 – "Compensation –Stock Compensation", which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The Company utilizes the Black-Sholes option pricing model and uses the simplified method to determine expected term because of lack of sufficient exercise history. Additionally, effective January 1, 2017, the Company adopted the Accounting Standards Update No. 2016-09 ("ASU 2016-09"), Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 permits the election of an accounting policy for forfeitures of share-based payment awards, either to recognize forfeitures as they occur or estimate forfeitures over the vesting period of the award. The Company has elected to recognize forfeitures as they occur and the cumulative impact of this change did not have any effect on the Company's consolidated financial statements and related disclosures.
Pursuant to ASC 505-50 – "Equity-Based Payments to Non-Employees", all share-based payments to non-employees, including grants of stock options, are recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black-Scholes valuation model, we periodically reassessed the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and the Company adjusted the expense recognized in the consolidated financial statements accordingly.
Upon exercise of the stock options by the holder using the exercise methods delineated in the option contract, we issue new common shares from our unissued authorized stock.
Results of Operations
The following comparative analysis on results of operations was based primarily on the comparative unaudited condensed consolidated financial statements, footnotes and related information for the periods identified below and should be read in conjunction with the unaudited condensed consolidated financial statements and the notes to those statements for the six months ended June 30, 2018 and 2017, which are included elsewhere in this Form 10-Q. The results discussed below are for the three and six months ended June 30, 2018 and 2017.
Comparison of Results of Operations for Three and Six Months ended June 30, 2018 and 2017
Sales
For the three months ended June 30, 2018, sales amounted to $64,888 as compared to $120,444 for the three months ended June 30, 2017, a decrease of $55,556, or 46.1%. For the six months ended June 30, 2018, sales amounted to $141,285 as compared to $194,444 for the six months ended June 30, 2017, a decrease of $53,159, or 27.3% which was attributable to lack of working capital and marketing funds. Historically, we have generated revenue from product sales. Beginning in January 2017, C-Bond implemented a multiple product structure consisting of the glass strengthening technology platform with enhancements to address specific product verticals. This methodology produced the launch of C-Bond NanoShield in the fourth quarter of 2017 with the continued revenues from C-Bond I for window film and C-Bond II Ballistic Resistant products. We use multiple sales channels, including distributors and authorized dealers to generate revenues.
Cost of Goods Sold
Cost of goods sold is comprised primarily of inventory sold, packaging costs, and warranty costs. For the three months ended June 30, 2018, cost of sales amounted to $16,518 as compared to $32,897 for the three months ended June 30, 2017, a decrease of $16,379, or 49.8%. For the six months ended June 30, 2018, cost of sales amounted to $28,012 as compared to $41,622 for the six months ended June 30, 2017, a decrease of $13,610, or 32.7%. The decreases in cost of sales was primarily due to a decrease in sales mentioned above.
Gross Profit
For the three months ended June 30, 2018, gross profit amounted to $48,370, or 74.5% of sales, as compared to $87,547, or 72.7% of sales, for the three months ended June 30, 2017, a decrease of $39,177, or 44.7%. For the six months ended June 30, 2018, gross profit amounted to $113,273, or 80.2% of sales, as compared to $152,822, or 78.6% of sales, for the six months ended June 30, 2017, a decrease of $39,549, or 25.9%. These decreases in gross profits are primarily the result of a decrease is sales as discussed above.
Operating Expenses
For the three months ended June 30, 2018, operating expenses amounted to $2,259,248 as compared to $971,635 for the three months ended June 30, 2017, an increase of $1,287,613, or 132.5%. For the six months ended June 30, 2018, operating expenses amounted to $4,573,237 as compared to $2,096,820 for the six months ended June 30, 2017, an increase of $2,476,417, or 118.1%. For the three and six months ended June 30, 2018 and 2017, operating expenses consisted of the following:
|
|
Three months ended
June 30,
|
|
|
Six months ended
June 30,
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Compensation and related benefits, including stock based compensation charges
|
|
$
|
1,764,283
|
|
|
$
|
832,105
|
|
|
$
|
3,742,240
|
|
|
$
|
1,732,604
|
|
Research and development
|
|
|
51,345
|
|
|
|
22,112
|
|
|
|
68,605
|
|
|
|
105,389
|
|
Professional fees
|
|
|
343,559
|
|
|
|
24,471
|
|
|
|
563,232
|
|
|
|
33,702
|
|
General and administrative expenses
|
|
|
100,061
|
|
|
|
92,947
|
|
|
|
199,160
|
|
|
|
225,125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,259,248
|
|
|
$
|
971,635
|
|
|
$
|
4,573,237
|
|
|
$
|
2,096,820
|
|
Compensation and related benefits
For the three months ended June 30, 2018, compensation and related benefits increased by $932,178, or 112.0%, as compared to the three months ended June 30, 2017. For the six months ended June 30, 2018, compensation and related benefits increased by $2,009,636, or 116.0%, as compared to the six months ended June 30, 2017. These increases were due to an increase in stock-based compensation expense. During the three months ended June 30, 2018 and 2017, stock-based compensation related to the accretion of stock-option expense and other stock-based compensation amounted to $1,515,522 and $584,596, respectively, an increase of $930,926. During the six months ended June 30, 2018 and 2017, stock-based compensation related to the accretion of stock-option expense and other stock-based compensation amounted to $3,264,666 and $1,237,016, respectively, an increase of $2,027,650.
Research and development expenses consist primarily of contracted development services, third party testing laboratories and allocated overhead expenses. For the three months ended June 30, 2018, research and development expense increased by $29,233, or 132.2%, as compared to the three months ended June 30, 2017. For the six months ended June 30, 2018, research and development expense decreased by $36,784, or 34.9%, as compared to the six months ended June 30, 2017. The increase in research and development expense is primarily related to continued evolution of the fundamental solution chemistry. We believe continued investment is important to attaining our strategic objectives and expect research and development expenses to increase in the foreseeable future.
Professional Fees
For the three months ended June 30, 2018, professional fees increased by $319,088, or 1,303.9%, as compared to the three months ended June 30, 2017. This increase primarily related to an increase in legal fees of $189,807 incurred related to the Merger, an increase in accounting fees of $29,103 related audit fees and other accounting fees incurred, and the recording of stock-based consulting fees of $52,084. For the six months ended June 30, 2018, professional fees increased by $529,530, or 1,571.2%, as compared to the six months ended June 30, 2017. This increase primarily related to an increase in legal fees of $331,488 incurred related to the Merger, an increase in accounting fees of $78,256 related audit fees and other accounting fees incurred, and an increase in consulting fees including the recording of stock-based professional fees of $70,417.
General and Administrative
General and administrative expenses consist primarily of rent, insurance, depreciation expense, sale and marketing, delivery and freight, travel and entertainment, and other office expenses. For the three months ended June 30, 2018, general and administrative expenses increased by $7,114, or 7.7%, as compared to the three months ended June 30, 2017. For the six months ended June 30, 2018, general and administrative expenses decreased by $25,965, or 11.5%, as compared to the six months ended June 30, 2017. We expect our general and administrative expenses to increase due to the anticipated growth of our business.
Other Expense
For the three months ended June 30, 2018, other expenses increased by $394,299 as compared to the three months ended June 30, 2017. This increase was due to an increase in interest expense of $10,824 related to the amortization of debt discount and an increase in interest-bearing debt, and an increase in loss from extinguishment of debt of $383,475. For the six months ended June 30, 2018, other expenses increased by $432,061 as compared to the six months ended June 30, 2017. This increase was due to an increase in interest expense of $48,586 related to the amortization of debt discount and an increase in interest-bearing debt, and an increase in loss from extinguishment of debt of $383,475. During the three and six months ended, we recorded loss on debt extinguishment related to the issuance 315,957 shares to a vendor to settle amounts owed to such vendor whereby we recorded settlement expense of $153,779, and due to a note termination agreement whereby we recorded debt extinguishment expense of $229,696.
Net Loss
For the three months ended June 30, 2018, net loss amounted to $2,605,594, or $0.04 per common share (basic and diluted), as compared to $884,505, or $0.02 per common share (basic and diluted), for the three months ended June 30, 2017, an increase of $1,721,089. For the six months ended June 30, 2018, net loss amounted to $4,892,442, or $0.08 per common share (basic and diluted), as compared to $1,944,415, or $0.04 per common share (basic and diluted), for the six months ended June 30, 2017, an increase of $2,948,027. The increase in net loss was primarily attributable to an increase in stock-based compensation expense, a reduction of gross profit and an increase in professional fees as discussed above.
Liquidity and Capital Resources
Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. We had cash of $498,523 and $46,448 of cash as of June 30, 2018 and December 31, 2017, respectively.
Our primary uses of cash have been for salaries, fees paid to third parties for professional services, research and development expense, and general and administrative expenses. We have received funds from the sales of products and from various financing activities such as from the sale of our common shares and from debt financings. The following trends are reasonably likely to result in changes in our liquidity over the near to long term:
|
●
|
An increase in working capital requirements to finance our current business,
|
|
●
|
Research and development fees;
|
|
●
|
Addition of administrative and sales personnel as the business grows, and
|
|
●
|
The cost of being a public company.
|
From inception in 2013 through December 31, 2017, we raised a total of $5.9 million from proceeds from the sale of common shares to fund its operations and research and development initiatives. Fund sources came from individual investment vehicles. No institutional investment has been made in the Company to date.
During 2017, we issued 514,455 common shares for cash proceeds of $437,500, or $0.85 per common share.
On June 1, 2017, we received $100,000 from a third party pursuant to the terms of a convertible promissory note (the "Convertible Note"). The Convertible Note accrued interest at 7% per annum and all principal and interest was payable on the maturity date of June 1, 2019. On April 1, 2018, the note and related accrued interest was converted into 136,894 common shares.
On January 22, 2018 (the "Issuance Date"), we entered into a securities purchase agreement (the "SPA") with Esousa Holdings, LLC ("Esousa"), whereby Esousa agreed to invest up to $750,000 (the "Purchase Price") in C-Bond Systems, LLC in exchange for senior secured convertible notes and five-year warrants, upon the terms and subject to the conditions thereof. Pursuant to the SPA, we issued (i) a senior secured convertible note to Esousa on January 22, 2018, in the original principal amount of $260,000, which bears interest at 10% per annum (the "First Note") and (ii) 293,123 five-year warrants to purchase shares of C-Bond common stock at a purchase price of $0.87 per share. On January 22, 2018, C-Bond received cash proceeds of $260,000 under this convertible note. Each convertible note issued pursuant to the SPA was due and payable two years from the issuance date of the respective convertible note, and any accrued and unpaid interest relating to each convertible note, was due and payable semi-annually.
Esousa was entitled to, at any time or from time to time, convert each convertible note issued under the SPA into our common shares, at a conversion price per share (the "Conversion Price") equal to $0.87 (subject to adjustment as provided in the First Note). The First Note contained various covenants, such as rights of first refusal, restrictions on the incurrence of indebtedness, creation of liens, payment of restricted payments, redemptions, payment of cash dividends and the transfer of assets. C-Bond also entered into a registrations rights agreement with Esousa which has been terminated. On April 26, 2018, C-Bond paid off the Esousa First Note, described below, for $270,000 and the parties terminated all of the related agreements, including the notes, the warrants and the registrations rights agreement.
During the six months ended June 30, 2018, we issued 323,373 common shares upon the exercise of 100,000 stock options at $0.031 per share. In connection with this option exercise, C-Bond received proceeds of $10,000. In April 2018, we issued 970,120 common shares upon the exercise of 300,000 stock options at $0.031 per share. In connection with these option exercises, we received proceeds of $30,000.
In April 2018, we issued 32,337 common shares to an investor for cash proceeds of $27,500, or $0.85 per common share.
Contemporaneously with the closing of the Merger, pursuant to subscription agreements, we issued an aggregate of 3,100,000 shares of Common Stock at a price of $0.40 per share for aggregate gross consideration of approximately $1,240,000 to six accredited investors. We agreed to file a shelf registration statement registering all of the shares of Common Stock subscribed for hereby (but no other shares owned by Subscriber) as soon as reasonably practicable after completion of the Merger and to use commercially reasonable efforts to cause that registration statement to be declared effective as soon as reasonably practical.
Additional cash liquidity is generated from product sales. We have not incurred any debt financing resulting in an extended liability.
To date, we are not profitable, and we cannot provide any assurances that we will be profitable. We believe our cash and cash equivalents will not provide sufficient capital to satisfy anticipated operational and research expense through a period of 12 months from the date of this report.
Cash Flows
For the Six Months Ended June 30, 2018 and 2017
The following table shows a summary of our cash flows for the six months ended June 30, 2018 and 2017.
|
|
Six Months Ended
June 30,
|
|
|
|
2018
|
|
|
2017
|
|
Net cash used in operating activities
|
|
$
|
(1,042,826
|
)
|
|
$
|
(647,893
|
)
|
Net cash provided by (used in) investing activities
|
|
$
|
187,401
|
|
|
$
|
(3,101
|
)
|
Net cash provided by financing activities
|
|
$
|
1,307,500
|
|
|
$
|
100,000
|
|
Net decrease in cash
|
|
$
|
452,075
|
|
|
$
|
(550,994
|
)
|
Cash - beginning of the period
|
|
$
|
46,448
|
|
|
$
|
596,910
|
|
Cash - end of the period
|
|
$
|
498,523
|
|
|
$
|
45,916
|
|
Net cash flow used in operating activities was $1,042,826 for the six months ended June 30, 2018 as compared net cash flow used in operating activities to $647,893 for the six months ended June 30, 2017, an increase of $394,933. Net cash flow used operating activities for the six months ended June 30, 2018 primarily reflected a net loss of $4,892,442, which was then adjusted for the add-back of non-cash items consisting of depreciation and amortization of $17,557, stock-based compensation expense of $3,194,249, stock-based professional fees of $70,417, loss on debt extinguishment expense of $380,171, and the amortization of debt discount to interest expense of $40,691, and changes in operating assets and liabilities primarily consisting of an increase in accounts payable of $119,997. Net cash flow used operating activities for the six months ended June 30, 2017 primarily reflected a net loss of $1,944,415, which was then adjusted for the add-back of non-cash items consisting of depreciation and amortization of $18,915 and stock-based compensation expense of $1,237,016, and changed in operating assets and liabilities consisting of an increase in accounts receivable of $48,413, an increase in accounts payable of $55,379, and an increase in accrued compensation of $30,534.
For the six months ended June 30, 2018, net cash flow provided by investing activities amounted to $187,401 as compared to net cash used in investing activities of $3,101. During the six months ended June 30, 2018, we received cash of $187,401 in connection with the merger transaction discussed elsewhere. During the six months ended June 30, 2017, we used cash of $3,101 for the purchase of property and equipment.
Net cash provided by financing activities was $1,307,500 for the six months ended June 30, 2018 as compared to $100,000 for the six months ended June 30, 2017. During the six months ended June 30, 2018, we received net proceeds from the sale of common stock of $1,267,500 and proceeds from the exercise of stock options of $40,000. During the six months ended June 30, 2017, we received net proceeds from convertible debt of $100,000.
Funding Requirements
We expect the primary use of capital to continue to be salaries, third party outside research and testing services, product and research supplies, legal and regulatory expenses and general overhead costs. Additional uses of capital will include additional headcount, tools and equipment, capacity expansion and operational control software. We believe our current cash and cash equivalents will not be sufficient to meet anticipated cash requirements not including potential product sales. Additional capital may be required to further research new product verticals and enhancements to current product offerings based on customer requirements.
As of June 30, 2018, we determined that there was substantial doubt about our ability to maintain operations as a going concern. Our consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Management cannot provide assurance that we will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. We will seek to raise capital through additional debt and/or equity financings to fund operations in the future. Although we have historically raised capital from sales of member units, from the sale of common shares, and from the issuance of convertible promissory notes, there is no assurance that it will be able to continue to do so. If we are unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations. Our consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong and could utilize our available capital resources sooner than we currently expect. Our capital requirements are difficult to forecast.
Until such time as we generate substantial product revenue to offset operational expenses, we expect to finance our cash needs through a combination of public and private equity offerings, debt financing, collaborative research and licensing agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition.
Contractual Obligations and Commitments
We have no long term debt obligations as of the date of this Report. We do maintain financing on two test equipment assets totaling a monthly expense of $3,220 that expire at the end of 2018. The current facility lease of $5,765 a month expires at the end of November 2018. We expect to enter into a new lease at that time.
We enter into agreements in the normal course of business with contracted research and testing organization, product distribution and material vendors which are payable or cancelable at any time with 30 day prior written approval.
Off-balance Sheet Arrangements
We do not have any off-balance sheet arrangements during the period presented as defined in the rules and regulations of the SEC.
Quantitative and Qualitative Disclosures About Market Risk
The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. Some of the securities that we invest in may have market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. We do not have any debt outstanding at the current time with floating interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, money market funds, government and non-government debt securities and corporate obligations.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure controls and procedures
We maintain "disclosure controls and procedures," as that term is defined in Rule 13a-15(e), promulgated by the SEC pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of June 30, 2018, our disclosure controls and procedures were not effective.
The ineffectiveness of our disclosure controls and procedures was due to the following material weaknesses in our internal control over financial reporting: (1) the lack of multiples levels of management review on complex accounting and financial reporting issues, (2) a lack of adequate segregation of duties and necessary corporate accounting resources in our financial reporting process and accounting function as a result of our limited financial resources to support hiring of personnel and implementation of accounting systems, and (3) lack of inventory controls. To remediate this situation we have engaged outsourced accountants. It is likely that we will continue to report material weaknesses in our internal control over financial reporting.
A material weakness is a deficiency or a combination of control deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
Changes in internal control over financial reporting
There were no changes in our internal control over financial reporting during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 1A. RISK FACTORS
Not applicable to smaller reporting companies.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
In April 2018, the Company issued 32,337 common shares to an investor for cash proceeds of $27,500, or $0.85 per common share.
Contemporaneously with the closing of the Merger, pursuant to subscription agreements, the Company issued an aggregate of 3,100,000 shares of common stock at a price of $0.40 per share for aggregate gross consideration of approximately $1,240,000 to six accredited investors. The Company agreed to file a shelf registration statement registering all of the shares of Common Stock subscribed for hereby (but no other shares owned by Subscriber) as soon as reasonably practicable after completion of the Merger and to use commercially reasonable efforts to cause that registration statement to be declared effective as soon as reasonably practical.
In April 2018, the Company issued 315,957 shares to a vendor to settle amounts owed to such vendor which were valued at $268,694, or $0.85 per common share, based on contemporaneous common share sales. In connection with the settlement agreement, the Company recorded settlement expense of $153,779 and reduced accounts payable and accrued expenses by $39,915 and $75,000, respectively.
During the six months ended June 30, 2018, the Company issued 1,293,492 common shares upon the exercise of 400,000 stock options at $0.031 per share. In connection with this option exercise, the Company received proceeds of $40,000.
In April 2018, the Company issued 3,233,732 restricted common shares to employees for services rendered which were valued at $2,750,000, or $0.85 per common share, based on contemporaneous common share sales. These share vest on May 1, 2019.
On March 7, 2018, the Company entered into a 90-day consulting agreement for business development and lobbying services related to the Company's ballistic resistant technologies. In connection with this consulting agreement, the Company issued 80,843 common shares to the consultant which were valued at $68,750, or $0.85 per common share, based on contemporaneous common share sales, which was amortized over the term of the agreement. Additionally, on June 12, 2018, the Company entered into a six months consulting agreement with this consultant. In connection with this consulting agreement, the Company issued 50,000 common shares to the consultant which were valued at $20,000, or $0.40 per common share, based on contemporaneous common share sales, which will be amortized over the term of the agreement. In connection with these consulting agreements, during the six months ended June 30, 2018, the Company recorded stock-based professional fees of $70,417, and prepaid expenses of $18,333 which will be amortized over the remaining term.
The above securities were issued in reliance upon the exemptions provided by Section 4(a) (2) under the Securities Act of 1933, as amended.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS*
|
|
XBRL INSTANCE DOCUMENT
|
101.SCH*
|
|
XBRL TAXONOMY EXTENSION SCHEMA
|
101.CAL*
|
|
XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
|
101.DEF*
|
|
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
|
101.LAB*
|
|
XBRL TAXONOMY EXTENSION LABEL LINKBASE
|
101.PRE*
|
|
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
|
* Filed herewith.
# Indicates a management contract or any compensatory plan, contract or arrangement.